1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Boehringer Ingelheim Reveals Battle Plans For Olmutinib

 
• By Alexandra Shimmings

Boehringer Ingelheim has revealed its Phase III plans for its third-generation EGFR inhibitor, olmutinib, a product that was recently approved in its first market, South Korea, but still faces significant competition in this crowded area.

Boehringer Ingelheim GMBH Boehringer Ingelheim has announced Phase III plans in non-small cell lung cancer for olmutinib, the third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI) it licensed from Hanmi Pharmaceutical Co. Ltd. last July.

Following the product's recent success in its originator's home market, South Korea, BI says it will comprehensively investigate olmutinib as a monotherapy in the ELUXA clinical trial program in a range of settings as well as in combination with investigational and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D